Stock analysis, AI verdict, fundamentals & technical signals
Rating: NEUTRAL
Price: $8.48 Analyst target: $14.20 Upside: 67.45%
Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. The company is headquartered in San Carlos, California.
See the full interactive analysis & chart →Informational only — not investment advice.